Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2010-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the objective response rate, safety and identify
potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin
injection given on a 28-day cycle.